Zhongbo Juli
VC Fund
Chaoyang, China
Zhongbo Juli is a VC fund in Chaoyang focused on Biotechnology and Medical. The company has many years of experience in investment consulting for central enterprises, and has super soft investment power.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Zhongbo Juli invests in
Stages Zhongbo Juli invests in
Countries Zhongbo Juli invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Guo Chen
|
|||
|
Kang Yaoyun
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 7 (41%)
- Medical 4 (24%)
- Manufacturing 4 (24%)
- Semiconductor 3 (18%)
- Pharmaceutical 3 (18%)
Stage
- Series A 6 (35%)
- Seed 4 (24%)
- Series B 4 (24%)
- Series C 2 (12%)
- Series D 1 (6%)
Country
- China 15 (88%)
- United Kingdom 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Guo Chen
Partner and Chief Investment Officer
|
Partner and Chief Investment Officer | Total investments: 1 | Find email | |
|
Kang Yaoyun
Chairman
|
Chairman | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Astribot
|
Astribot is a developer of consumer humanoid robots and integrated bionic robots. | $147.8M / Series B / Jun 03, 2026 | |
Yaozheng Quantum Technology
|
UnitQC is a China‑based quantum technology company focused on trapped‑ion quantum computing systems and related products. | Seed / Mar 29, 2026 | |
Luojia Yiyun
|
Luojia Yiyun is a high-end laser scanning detection equipment developer company that specializes in lightweight, high-precision, high-performance, and independent intellectual property laser radar devices. | Seed / Mar 16, 2026 | |
Enze Kangtai
|
Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research. | $14M / Series B / Nov 06, 2025 | |
Null Hypothesis
|
Null Hypothesis is an AI medical SaaS company that focuses on the development of intelligent medical products using AIGC. | Series B / Sep 06, 2024 | |
Shenji Changhua
|
Shenji Changhua is a biotechnology company focusing on neurological diseases such as ALS. | $13.8M / Seed / Aug 01, 2024 | |
Binhui Biotech
|
Wuhan Binhui Biotechnology Co., Ltd. was established in 2010. The company is located in the Optics Valley Bio City of Donghu National Independent Innovation Demonstration Zone. The company is committed to providing innovative products and services for the field of oncology integration (including diagnosis and treatment), and developing products andservices that have independent intellectual property rights and can compete with other manufacturers on the international stage. | Series C / Apr 17, 2024 | |
HemaCell
|
Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish aplatform using platelet cells as a drug delivery carrier. | Series A / Dec 19, 2023 | |
Linkwise Technology
|
Linkwise Technology is a semiconductor company that provides material handling automation system (AMHS) solutions for semiconductor production line logistics. | Series A / Oct 16, 2023 | |
Zenosic
|
Zenosic focuses in the design and R&D of high-performance network chips, along with offering leading chip products for cloud service providers, equipment makers, operators, and diverse industries. | $41.9M / Series A / Sep 06, 2023 | |
| See all 17 investments → | |||
Co-Investors
Ant Group
1 deal together
Baidu Capital
1 deal together
Broad Vision Funds
1 deal together
CAS Investment Management
1 deal together
CAS Star
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Zhongbo Juli invest in?
Zhongbo Juli invests primarily in Biotechnology, Medical and Manufacturing startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Zhongbo Juli?
Public channels for Zhongbo Juli include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Zhongbo Juli?
The team at Zhongbo Juli includes Guo Chen (Partner and Chief Investment Officer) and Kang Yaoyun (Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
